Cargando…

Synergistic effect of HDAC inhibitor Chidamide with Cladribine on cell cycle arrest and apoptosis by targeting HDAC2/c-Myc/RCC1 axis in acute myeloid leukemia

BACKGROUND: More effective targeted therapy and new combination regimens are needed for Acute myeloid leukemia (AML), owing to the unsatisfactory long-term prognosis of the disease. Here, we investigated the synergistic effect and the mechanism of a histone deacetylase inhibitor, Chidamide in combin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gu, Siyu, Hou, Yue, Dovat, Katarina, Dovat, Sinisa, Song, Chunhua, Ge, Zheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9972767/ https://www.ncbi.nlm.nih.gov/pubmed/36849955 http://dx.doi.org/10.1186/s40164-023-00383-5

Ejemplares similares

PB1784: CLADRIBINE SYNERGIZES THE EFFECT OF VENETOCLAX ON CELL PROLIFERATION ARREST AND APOPTOSIS BY TARGETING DNA-PKCS/C-MYC SIGNALING IN ACUTE MYELOID LEUKEMIA
por: Hou, Yue, et al.
Publicado: (2023)

Preclinical Evaluation of the HDAC Inhibitor Chidamide in Transformed Follicular Lymphoma
por: Zhong, Mengya, et al.
Publicado: (2021)

Frequent amplification of HDAC genes and efficacy of HDAC inhibitor chidamide and PD-1 blockade combination in soft tissue sarcoma
por: Que, Yi, et al.
Publicado: (2021)

Chidamide Suppresses the Growth of Cholangiocarcinoma by Inhibiting HDAC3 and Promoting FOXO1 Acetylation
por: Li, Yongpan, et al.
Publicado: (2022)

Clinical significance of high c-MYC and low MYCBP2 expression and their association with Ikaros dysfunction in adult acute lymphoblastic leukemia
por: Ge, Zheng, et al.
Publicado: (2015)

Chidamide induces apoptosis in DLBCL cells by suppressing the HDACs/STAT3/Bcl-2 pathway
por: Zhang, Hongwei, et al.
Publicado: (2021)

Ikaros regulation of the BCL6/BACH2 axis and its clinical relevance in acute lymphoblastic leukemia
por: Ge, Zheng, et al.
Publicado: (2016)

P344: ONCOGENESIS OF CRLF2 OVEREXPRESSION AND EFFECT OF A NOVEL JAK2 INHIBITOR IN CRLF2 OVEREXPRESSED B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
por: Gu, Yan, et al.
Publicado: (2023)

Epigenetic regulation of gene expression by Ikaros, HDAC1 and Casein Kinase II in leukemia
por: Song, C, et al.
Publicado: (2016)

c-Myc suppresses miR-451⊣YWTAZ/AKT axis via recruiting HDAC3 in acute myeloid leukemia
por: Su, Rui, et al.
Publicado: (2016)

HDAC Inhibitors in Acute Myeloid Leukemia
por: San José-Enériz, Edurne, et al.
Publicado: (2019)

Chidamide and apatinib are therapeutically synergistic in acute myeloid leukemia stem and progenitor cells
por: Zhao, Haijun, et al.
Publicado: (2022)

Chidamide increases the sensitivity of refractory or relapsed acute myeloid leukemia cells to anthracyclines via regulation of the HDAC3 -AKT-P21-CDK2 signaling pathway
por: Wang, Hao, et al.
Publicado: (2020)

Synergistic effect of chidamide and venetoclax on apoptosis in acute myeloid leukemia cells and its mechanism
por: Li, Gangping, et al.
Publicado: (2021)

Expression of Histone Deacetylases HDAC1, HDAC2, HDAC3, and HDAC6 in Invasive Ductal Carcinomas of the Breast
por: Seo, Jinwon, et al.
Publicado: (2014)

Clinicopathological features and prediction values of HDAC1, HDAC2, HDAC3, and HDAC11 in classical Hodgkin lymphoma
por: Huang, Renhong, et al.
Publicado: (2018)

The TGF-β/HDAC7 axis suppresses TCA cycle metabolism in renal cancer
por: Nam, Hyeyoung, et al.
Publicado: (2021)

Novel HDAC inhibitor Chidamide synergizes with Rituximab to inhibit diffuse large B-cell lymphoma tumour growth by upregulating CD20
por: Guan, Xu-Wen, et al.
Publicado: (2020)

Involvement of HDAC1 and HDAC3 in the Pathology of Polyglutamine Disorders: Therapeutic Implications for Selective HDAC1/HDAC3 Inhibitors
por: Thomas, Elizabeth A.
Publicado: (2014)

WDR5 high expression and its effect on tumorigenesis in leukemia
por: Ge, Zheng, et al.
Publicado: (2016)

The Synergistic Anti-Tumor Activity of EZH2 Inhibitor SHR2554 and HDAC Inhibitor Chidamide through ORC1 Reduction of DNA Replication Process in Diffuse Large B Cell Lymphoma
por: Wang, Xing, et al.
Publicado: (2021)

HDAC and HDAC Inhibitor: From Cancer to Cardiovascular Diseases
por: Yoon, Somy, et al.
Publicado: (2016)

A novel conditioning regimen of chidamide, cladribine, gemcitabine, and busulfan in the autologous stem cell transplantation of aggressive T-cell lymphoma
por: Zeng, Qiang, et al.
Publicado: (2023)

HDAC3 and HDAC8 are required for cilia assembly and elongation
por: Park, Seon-ah, et al.
Publicado: (2019)

Metabolism, HDACs, and HDAC Inhibitors: A Systems Biology Perspective
por: King, Jacob, et al.
Publicado: (2021)

Novel HDAC inhibitor MAKV-8 and imatinib synergistically kill chronic myeloid leukemia cells via inhibition of BCR-ABL/MYC-signaling: effect on imatinib resistance and stem cells
por: Lernoux, Manon, et al.
Publicado: (2020)

The HDAC Inhibitor LBH589 Induces ERK-Dependent Prometaphase Arrest in Prostate Cancer via HDAC6 Inactivation and Down-Regulation
por: Chuang, Mei-Jen, et al.
Publicado: (2013)

HDAC-inhibitor (S)-8 disrupts HDAC6-PP1 complex prompting A375 melanoma cell growth arrest and apoptosis
por: Balliu, Manjola, et al.
Publicado: (2015)

HDAC6—An Emerging Target Against Chronic Myeloid Leukemia?
por: Losson, Hélène, et al.
Publicado: (2020)

Characterization of LEF1 High Expression and Novel Mutations in Adult Acute Lymphoblastic Leukemia
por: Guo, Xing, et al.
Publicado: (2015)

Synergistic Interactions between HDAC and Sirtuin Inhibitors in Human Leukemia Cells
por: Cea, Michele, et al.
Publicado: (2011)

Synergistic Antitumor Effects of Novel HDAC Inhibitors and Paclitaxel In Vitro and In Vivo
por: Zuco, Valentina, et al.
Publicado: (2011)

Hydroxamic acid derivatives as HDAC1, HDAC6 and HDAC8 inhibitors with antiproliferative activity in cancer cell lines
por: Sixto-López, Yudibeth, et al.
Publicado: (2020)

Continuous Activity Assay for HDAC11 Enabling Reevaluation of HDAC Inhibitors
por: Kutil, Zsófia, et al.
Publicado: (2019)

The Synergistic Antitumor Activity of Chidamide in Combination with Bortezomib on Gastric Cancer
por: Zhang, Wanjun, et al.
Publicado: (2020)

HDAC inhibitor PAC-320 induces G2/M cell cycle arrest and apoptosis in human prostate cancer
por: Dong, Zhixiong, et al.
Publicado: (2017)

HDAC9-mediated epithelial cell cycle arrest in G2/M contributes to kidney fibrosis in male mice
por: Zhang, Yang, et al.
Publicado: (2023)

HDAC8: A Promising Therapeutic Target for Acute Myeloid Leukemia
por: Spreafico, Marco, et al.
Publicado: (2020)

HDAC2‐dependent miRNA signature in acute myeloid leukemia
por: Conte, Mariarosaria, et al.
Publicado: (2019)

Targeting the NANOG/HDAC1 axis reverses resistance to PD-1 blockade by reinvigorating the antitumor immunity cycle
por: Oh, Se Jin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_b5rgdq884it7a6t92m1ji8t8um